RecruitingPhase 4NCT05596526

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

Immunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric Study

Sponsor

Prof Patrice Lalive

Enrollment

100 participants

Start Date

Dec 1, 2022

Study Type

INTERVENTIONAL

Conditions

Shingles Zoster

Summary

The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how well a shingles vaccine (called the Recombinant Zoster Vaccine) works in people with multiple sclerosis (MS) who are on a specific type of medication. Because some MS drugs suppress the immune system, researchers want to know if the vaccine still builds enough protection. **You may be eligible if...** - You are 18 or older - You have relapsing MS (a form where symptoms come and go) - You have not yet received the shingles vaccine (RZV) - You have been on an anti-CD20 treatment (like Ocrelizumab) for at least one year **You may NOT be eligible if...** - You have already received the shingles vaccine being studied - You do not have the relapsing form of MS - You have not been on the required MS medication for at least a year Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility

Interested in this trial?

Get notified about updates and connect with the research team.